By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display

Dow AgroSciences LLC 

Shire 

Sigma-Aldrich 

Sangamo 





Company News
Biogen (BIIB) in Negotiations to Unload Cambridge Manufacturing Facility 6/24/2016 7:02:55 AM
Biogen (BIIB) Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology 6/21/2016 10:18:10 AM
Biogen (BIIB) To Report Second Quarter 2016 Financial Results On July 21, 2016 6/21/2016 9:50:54 AM
5 Biotech Stocks at Bargain Basement Prices 6/21/2016 7:42:08 AM
Biogen (BIIB)'s Cambridge Manufacturing Move Means More Work for the 1,300 Workers in North Carolina 6/20/2016 6:36:04 AM
285 Jobs at Risk as Biogen (BIIB) to Stop Producing Drugs at Its Cambridge Plant 6/17/2016 7:14:48 AM
ASCO Winners And Losers And Biogen (BIIB)'s Discouraging Failure 6/13/2016 7:13:53 AM
Amid Plunging Stocks and Failed Trials, Biogen (BIIB)’s CIO Quietly Leaves Company 6/10/2016 7:20:49 AM
New Data Presented At The Annual European Congress Of Rheumatology (EULAR 2016) Demonstrate Safety And Efficacy Of Biogen (BIIB)’s Anti-TNF Biosimilars Portfolio 6/9/2016 8:17:45 AM
Biogen (BIIB)'s $8 Billion Market Cap Drop Makes Thermo Fisher Scientific (TMO) the New King in Massachusetts, But GE Corporation (GE)’s Coming to Town 6/9/2016 6:15:26 AM
12345678910...
//-->